We report a case of infection with Candida glabrata in which the organism became resistant to fluconazole and in which pre-and posttreatment isolates were available for comparison. The organism was cross-resistant to ketoconazole and itraconazole, in common with other azole-resistant yeasts. Fluconazole was a potent inhibitor of cytochrome P-450-dependent 14a-sterol demethylase (P-450DM) in lysates of cells from both susceptible and resistant cultures (50%o inhibitory concentration, 0.2 FM), indicating that resistance was unrelated to changes in P-450DM-Instead, it appeared to arise from a permeability barrier to fluconazole, since resistant celis were unable to take up radiolabelled drug.
The azole (N-substituted imidazole or triazole) class of antifungal antibiotics is used commonly in the treatment of both superficial and deep-seated mycoses, including candidiases (6) . These drugs most probably work by inhibiting ergosterol biosynthesis in fungal cells by binding to P-450-dependent 14a-sterol demethylase (P-450DM), an important enzyme in ergosterol biosynthesis (7) . This leads to the accumulation of methylated sterols, which are thought to disrupt membrane structure and function (27) .
Clinical isolates of Candida vary widely in their susceptibilities to azoles, but only a small number of resistant strains have been isolated from treatment failures during more than 20 years of widespread use. In 1978, Holt and Azmi (14) described a case of candidiasis in a neonate in which resistance to miconazole developed in a strain of C albicans following 9 weeks of treatment for a urinary tract infection. Since then, four cases have been reported. In those cases prolonged ketoconazole treatment for chronic mucocutaneous candidiasis led to resistance in the infecting C. albicans strains (15, 20, 25) . Reports of fluconazole resistance are of very low incidence because the drug has been used to treat more than 15 million patients, including more than 250,000 patients infected with the AIDS virus. The small number of cases of resistance have been described following the treatment of candidiases in a seriously debilitated patient with hepatorenal failure (24) and in immunocompromised patients (4), including those with AIDS (5, 16, 19, 26) .
The known mechanisms of azole resistance in C. albicans may be divided broadly into two types: resistance caused by the decreased azole susceptibility of P-450DM, the target enzyme in ergosterol biosynthesis (9, 20) , or permeability resistance in cells unable to take up drug (8, 13, 18) . A recent report described both mechanisms in a fluconazole-resistant clinical isolate of C. glabrata (23) . Here we report a patient infected with C glabrata. The organism appeared to become resistant after 2 weeks of oral treatment with fluconazole, and pre-and posttreatment isolates were available for comparison. Like most azole-resistant C. albicans and C. glabrata strains, the isolate described here was cross-resistant to other azoles, including ketoconazole and itraconazole, and the mechanism of resistance appeared to be reduced drug uptake rather than changes at the level of ergosterol biosynthesis.
* Corresponding author.
CASE REPORT
A 69-year-old woman was admitted to the hospital on 10 October 1989 with bilateral pneumonia, anemia, and mild dysuria. She deteriorated further, and on 11 October she was transferred to the intensive therapy unit for ventilation, where she then suffered a large hematemesis. Laparotomy and gastrotomy revealed two chronic, benign gastric ulcers which were repaired. During the following week she remained ventilator dependent and was noted to have bilateral pleural effusions sufficient to warrant chest drain insertion on 17 October. This resulted in hemorrhage which necessitated thoracotomy to repair the damaged right lung; several empyemas were drained. She was again ventilated and, as a further complication, a computed tomography scan of her abdomen on 25 October showed a collection of fluid. Laparotomy revealed a splenic tear, and splenectomy was performed. A tracheostomy was also performed on 26 October.
Four urine specimens taken between 16 and 23 October yielded C. glabrata (Fig. 1) . Intermittent local instillation of amphotericin B was commenced on 24 October. Blood cultures taken from an arterial line on 25 and 29 October yielded Rhodotorula glutinis, and because the patient was febrile and colonized with C. glabrata, parenteral treatment with fluconazole (200 mg daily) was commenced on 30 October; local treatment with amphotericin B was discontinued. Four urine specimens taken during the following week were sterile, but R. glutinis was isolated from a blood culture taken on 3 November. However, subsequent blood cultures were sterile. Fluconazole treatment was discontinued on 12 November. In the meantime, the patient's condition had improved, enabling artificial ventilation and parenteral nutrition to be discontinued. However, urine and sputum specimens and throat and rectal swabs taken on 13 and 16 November revealed that she was still colonized with C. glabrata ( Fig. 1) . No further antifungal treatment was given, and the patient was discharged to a geriatric hospital on 5 December. 0, C. glabrata isolated; , fluconazole therapy; (, C. glabrata isolated (MIC, 12.5 p.g/ml); e, C. glabrata isolated (MIC, 100 pg/ml); 0, nothing isolated.
acid (specific radioactivity, 1.85 GBq/mmol), and [3H] fluconazole (specific radioactivity, 81.4 GBq/mmol).
Isolation and identification of C. glabrata from the patient. Samples from the patient were cultured on a range of media incubated at 37°C. Isolates of C. glabrata were identified by means of ID 32C identification strips (BioMerieux).
Cultures of C. glabrata isolated from urine (fluconazole susceptible, Y33.90; fluconazole resistant, Y33.91) were maintained in freeze-dried ampoules and were subcultured on slopes of Sabouraud dextrose agar before use. Lateexponential-phase cultures were grown in High Resolution Medium (HR; Oxoid) essentially as described previously (8) . The organisms were typed by restriction fragment length polymorphism (RFLP) analyses of genomic DNA (21) . The resulting RFLP patterns were qualitatively different, thereby suggesting that the organisms were clonally unrelated.
Azole susceptibility. The MICs of fluconazole, ketoconazole, and itraconazole for the C glabrata isolates were measured by broth macrodilution in HR medium (17) . The MIC was defined as the lowest drug concentration at which there was no visible growth.
Measurement of sterol biosynthesis in cells and lysates. 
RESULTS
Effect of fluconazole on cell growth. When tested by HR broth dilution assays, the resistant culture showed greatly reduced susceptibilities to fluconazole, ketoconazole, and itraconazole in comparison with those of the susceptible culture ( Table 1) .
Effects of fluconazole on sterol 14ca-demethylation. When cell lysates were incubated with [14C]mevalonic acid, approximately 40% of the total radioactivity in the assay was recovered in the NSF for both susceptible and resistant organisms. Sterols were separated from the other NSF components and were fractionated into desmethylated and 14a-methylated classes by one-dimensional thin-layer chro- matography by previously published methods (12) . The desmethylated and 14a-methylated sterol fractions comprise mainly ergosterol and lanosterol plus 4,14-dimethylzymosterol, respectively (22) . In control experiments 55 to 63% and 20 to 22% of the NSF radioactivity in both isolates was incorporated into ergosterol and 14a-methylated sterols, respectively. In experiments containing fluconazole to inhibit P-450DM, there was a dose-dependent decrease in the proportion of NSF radioactivity in ergosterol and a corresponding increase in the proportion of radioactivity in 14a-methylated sterols for both isolates (Fig. 2) . The same phenomena were observed in repeat experiments with cells incubated in HR broth containing [14C]acetic acid as the sterol precursor (Fig. 3) . reduced susceptibility of P-450DM to azoles (9, 20, 23 ratio (8, 10) . This ratio may influence considerably the 6. physical and biochemical properties of membranes, and 
